Organization
Exact Sciences Corporation
21 abstracts
Abstract
ECOG-ACRIN E2197: Comparison of HER2 gene expression by RT-PCR across all HER2 immunohistochemistry groups with recurrence analysis.Org: Exact Sciences Corporation, Genomic Health Inc, Fred Hutchinson Cancer Research Center, Tisch Cancer Institute, Fox Chase Cancer Center,
Abstract
Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).Org: Winship Cancer Institute, Emory University, Atlanta, GA, USA, Cancer Research and Biostatistics, University of Kansas Medical Center, ASCO,
Abstract
Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.Org: Exact Sciences Corporation, CRAB, Rabin Medical Center, Public Health Sciences Division, Department of Breast Medical Oncology,
Abstract
Updated SEER database study of 21-gene assay to assess breast cancer–specific mortality and benefit of chemotherapy by race and ethnicity.Org: Genomic Health Inc, Department of Biostatistics & Data Science, UPMC Hillman Cancer Center, Exact Sciences Corporation, National Cancer Institute/National Institutes of Health,
Abstract
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the Recurrence Score in node-positive breast cancer: Independent validation in the PACS-01 trial.Org: Exact Sciences Corporation, Gustave Roussy Cancer Center, Centre Léon Bérard, R&D Unicancer, Alliance for Clinical Trials in Oncology,
Abstract
Effect of multi-cancer early detection screening on late-stage cancers: A modeling study.Org: Value Analytics Labs, LLC, Exact Sciences Corporation, Memorial Sloan Kettering Cancer Center, Medical University of South Carolina, London School of Hygiene & Tropical Medicine,
Abstract
Time-to-diagnosis and peri-diagnostic healthcare utilization between screen- and non-screen detected cancers: Evidence from SEER-Medicare.Org: Exact Sciences Corporation, Curta, Inc., Curta Inc, Exact Sciences Corp., Mayo Clinic,
Abstract
Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.Org: Exact Sciences Corporation, Cancer Research and Biostatistics (CRAB), Seattle, WA, ASCO, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Loyola University Chicago Stritch School of Medicine,
Abstract
Long-term clinical outcomes of cancers diagnosed following detection by a blood-based multi-cancer early detection (MCED) test.Org: Geisinger Northeast, Johns Hopkins University School of Medicine, Exact Sciences Corporation,
Abstract
Outcomes in participants with a false positive multi-cancer early detection (MCED) test: Results from >4 years follow-up from DETECT-A, the first large, prospective, interventional MCED study.Org: Johns Hopkins University School of Medicine, Geisinger Northeast, Exact Sciences Corporation,
Abstract
SEER analysis of 9-year breast cancer specific mortality (BCSM) in patients (pts) with invasive lobular breast cancer (ILC) assessed by the 21-gene Breast Recurrence Score assay.Org: UPMC Hillman Cancer Center, Genomic Health Inc, NSABP Foundation, University of Pittsburgh, Pittsburgh, PA, Exact Sciences Corporation,
Abstract
The detection of multiple cancer types with an extended set of methylation and protein markers.Org: Exact Sciences Corporation,
Abstract
Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).Org: OHSU Knight Cancer Institute, Portland, OR, Boston University Chobanian & Avedisian School of Medicine, Exact Sciences Corporation, Oregon Health & Science University, University of Washington; Fred Hutchinson Cancer Center,
Abstract
Correlation of unobserved incidence of cancer in earlier stages with the observed incidence.Org: Value Analytics Labs, LLC, Exact Sciences Corporation,
Abstract
Estimated life-years gained and resultant cost savings from follow-up colonoscopy after a positive multi-target stool DNA (mt-sDNA) test for colorectal cancer screening in commercially insured and Medicare populations.Org: University of Michigan, Division of Gastroenterology and Hepatology, Mayo Clinic, Mayo Clinic, Exact Sciences Corporation,
Abstract
Colorectal cancer screening with blood-based tests: Estimated impact of a 1-, 2-, or 3-year screening interval compared with annual FIT and triennial mt-sDNA strategies.Org: University of Michigan, Ann Arbor, Millennium Pharmaceuticals, Division of Gastroenterology and Hepatology, Mayo Clinic, Mayo Clinic,
Abstract
Genomic profiling of biliary tract carcinomas by their location.Org: Exact Sciences Corporation, Phoenix, AZ, Redwood City, CA, Houston Methodist Cancer Center, Houston, TX,
Abstract
Validating the use of machine-learning cancer staging algorithms for Medicare cost analyses.Org: Milliman, Inc., Exact Sciences Corporation,
Abstract
Differentiating bladder cancer (BLCA) tumor immune microenvironment (TME) profiles based on predicted intrinsic radiosensitivity (RS).Org: Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Instititute, Exact Sciences Corporation, GenomOncology, University of Michigan,
Abstract
A flexible quantitative framework to assess the potential contribution of early cancer detection to improved cancer survival.Org: University of Wisconsin, Madison, Exact Sciences Corporation,
Abstract
Patient-provider communication factors associated with mt-sDNA screening for colorectal cancer.Org: Exact Sciences Corporation, Mayo Clinic, RTI International,